When “More Treatment” Is Not Automatically Better Treatment
IVF patients are frequently offered additional tests, medications, laboratory procedures, and technologies intended to improve the chance of pregnancy.
These optional interventions are often called treatment add-ons.
Some add-ons may have a defined role for a selected patient or may improve a specific aspect of treatment. Others remain experimental, have conflicting research, or have not been shown to improve live-birth outcomes despite attractive biological theories.
Patients who have experienced repeated failure are especially vulnerable to the idea that one missing test or procedure explains everything. The pressure to “try everything” can become stronger with each unsuccessful cycle.
At Jinemed, innovation is not rejected simply because it is new. It is evaluated through evidence, safety, clinical relevance, cost, ethics, and the individual patient’s diagnosis.
The central question is not “Can we add this?” It is “What problem are we trying to solve, and is there reliable evidence that this intervention helps solve it?”
What Is an IVF Add-On?
Core fertility treatment includes established steps such as appropriate evaluation, ovarian stimulation, monitoring, egg collection, fertilisation, embryo culture, transfer, and cryopreservation when indicated.
An add-on is an additional test, medication, laboratory method, or procedure offered alongside core treatment, often with a claim that it may improve pregnancy, reduce miscarriage, enhance embryo selection, or help patients with previous failure.
An intervention is not necessarily ineffective merely because it is called an add-on. The concern arises when it is:
- Offered routinely to patients without a defined indication
- Marketed as proven when evidence is uncertain
- Evaluated only through intermediate outcomes rather than live birth
- Sold without clear discussion of risk and cost
- Introduced into practice before adequate validation
- Used in place of correcting a known medical or laboratory problem
The same intervention may be appropriate for one patient, unnecessary for another, and suitable only within research for a third.
How Evidence Should Be Read
Not all scientific evidence provides the same level of confidence.
A laboratory study may show that a biological marker changes after treatment. An observational study may report higher pregnancy rates among patients who chose an add-on. A randomised controlled trial may compare the intervention with standard care. A systematic review may combine several studies.
Each design has strengths and limitations.
Add-on research is particularly vulnerable to bias because patients receiving the intervention may differ from those who do not. Clinics may introduce several changes at the same time. Studies may be small, use different patient groups, or measure pregnancy rather than live birth.
The outcome also matters. Evidence that an add-on:
- Changes a laboratory measurement
- Improves embryo grading
- Increases implantation per transfer
- Reduces miscarriage
- Shortens time to pregnancy
- Improves cumulative live birth
does not mean the same thing.
For most patients, live birth and safety are more meaningful than a favourable change in an intermediate marker.
The Five Questions Before Any Add-On
At Jinemed, an additional intervention should be evaluated through five questions:
- What specific clinical problem has been identified?
- What evidence supports this add-on for patients with that problem?
- Does it improve live birth, or only an intermediate outcome?
- What are the risks, uncertainties, costs, and alternatives?
- What would happen if standard treatment continued without it?
If the medical team cannot explain which problem the add-on addresses, the patient should not be asked to purchase it based only on fear of another failure.
PGT-A: Useful Information, Not Universal Treatment
Preimplantation Genetic Testing for Aneuploidy evaluates embryo-biopsy samples for chromosome-number abnormalities.
PGT-A may help select among several blastocysts and may reduce the transfer of embryos reported as aneuploid. It may be discussed according to age, embryo number, miscarriage history, previous outcomes, and the patient’s priorities.
However, PGT-A does not improve egg quality or create chromosomally normal embryos. A high success rate per euploid transfer begins only after eggs were collected, embryos reached blastocyst, biopsy produced a result, and at least one embryo was reported suitable.
Research does not show that PGT-A improves cumulative live birth for every IVF patient. Younger patients with several good-quality embryos, older patients, recurrent-loss patients, and patients with only one embryo represent different clinical questions.
PGT-A should therefore not be sold automatically after one failed cycle or simply because a patient wants the “best embryo.” The decision requires counselling about possible absence of a blastocyst, no euploid result, mosaic or inconclusive findings, embryo freezing, cost, and the limits of testing.
PGT-M and PGT-SR are different. They address a known single-gene condition or structural chromosomal rearrangement and should not be grouped with general aneuploidy screening.
Assisted Hatching
An embryo is surrounded by a protective outer layer called the zona pellucida. Assisted hatching uses a technique—commonly a laser—to create an opening or thinning in this layer before transfer.
The theory is that this may help the embryo emerge and implant. The technique has been offered to patients with advanced age, previous failed transfers, frozen embryos, or a thick zona.
However, routine assisted hatching has not consistently been shown to improve live-birth rates in the general IVF population. It also introduces an additional laboratory manipulation.
Its use should be based on a defined laboratory or clinical rationale rather than being included automatically in every cycle as a sign of “advanced IVF.”
Time-Lapse Imaging
Time-lapse incubators photograph embryos at frequent intervals without requiring repeated removal for conventional observation.
This can provide detailed developmental information and may support stable culture conditions, laboratory documentation, education, and research.
Algorithms may also use developmental timing to rank embryos.
The availability of more images, however, does not automatically prove that time-lapse selection improves cumulative live birth compared with good standard culture and experienced embryology assessment.
Time-lapse technology may offer operational and observational value. Patients should be told whether it is being used as part of the laboratory system, whether an extra fee is charged, and what patient outcome the clinic claims it improves.
More data are useful only when the interpretation is reliable and changes care meaningfully.
Artificial Intelligence in Embryo Assessment
Artificial intelligence is being developed to assist embryo grading, image analysis, witnessing, workflow, and cryostorage management.
AI may identify patterns that are difficult to assess consistently by eye. It may also support standardisation and reduce repetitive workload.
Yet an algorithm is influenced by the data used to train it. A system developed on one laboratory’s patients, equipment, and embryo images may not perform identically in another setting. Bias, data quality, explainability, validation, privacy, and responsibility for decisions remain important.
AI should support qualified embryologists rather than create the impression that a computer can guarantee which embryo will become a baby.
Before clinical adoption, a system should be validated in the environment where it will be used, monitored after implementation, and integrated into the laboratory quality programme.
Endometrial Receptivity Testing
Endometrial receptivity tests analyse a sample of the uterine lining, often with the aim of estimating whether the timing of progesterone exposure matches a proposed “window of implantation.”
These tests are frequently marketed to patients with repeated failed transfers. A personalised transfer time may appear logically attractive.
However, the endometrium is biologically complex, biopsy results may not represent every future cycle, and evidence has not established routine receptivity testing as beneficial for all patients with failed implantation.
Before considering such a test, the team should review embryo quality, uterine anatomy, transfer technique, endometrial preparation, progesterone timing, and whether failures exceed what may be expected statistically.
An expensive test should not substitute for reconstructing the basic treatment history.
Endometrial Scratching
Endometrial scratching intentionally creates a small injury to the uterine lining before a treatment cycle, based on the theory that the healing response may support implantation.
Early studies produced interest, particularly for recurrent implantation failure. Later and larger research has not provided consistent evidence of improved live birth for routine use.
The procedure can cause pain, bleeding, infection risk, inconvenience, and additional cost.
It should not be presented as a harmless step that every patient may as well try. If considered, the clinical reason and uncertainty should be explained clearly.
Immune Testing and Immunotherapy
The immune system plays an important role in reproduction, but this biological truth does not validate every commercial immune test or treatment.
Patients may be offered:
- Natural killer cell testing
- Cytokine panels
- HLA or other immune matching
- Intralipid infusion
- Intravenous immunoglobulin
- Corticosteroids
- Colony-stimulating factors
- Other immune-modulating medication
Many tests lack standardised thresholds or a demonstrated connection between an abnormal result and a treatment that improves live birth.
Immune-modulating treatments can create medical risk, including infection, allergic reaction, metabolic effects, and complications related to immune suppression or infusion.
The fact that a pregnancy involves the immune system does not mean that unexplained failure should automatically be treated as immune rejection.
Immunotherapy should not be offered routinely without a defined indication and reliable evidence.
Anticoagulants and Aspirin
Aspirin or heparin may be medically indicated for selected patients with specific diagnoses, such as antiphospholipid syndrome or another established reason determined by the appropriate physician.
They should not be prescribed to every IVF patient or every patient after miscarriage based on the assumption that implantation failure is caused by “thick blood.”
These medications can cause bleeding and other complications. A positive result on a broad, non-targeted panel may not justify treatment.
The diagnosis, expected benefit, dose, duration, and monitoring plan should be clear before anticoagulant therapy is added.
Platelet-Rich Plasma and “Ovarian Rejuvenation”
Platelet-rich plasma, commonly called PRP, has been injected into ovaries or the uterine cavity with claims that it may improve ovarian reserve, egg production, endometrial thickness, or implantation.
The term “ovarian rejuvenation” is particularly powerful marketing language because it suggests that ovarian ageing can be reversed.
Current evidence does not justify promising that PRP restores a younger ovary, creates new eggs, or reliably improves live birth. Procedures involving ovarian injection also carry procedural risk.
PRP in reproductive medicine should be described as experimental unless high-quality evidence and applicable professional guidance support a defined use.
Patients with low AMH should not be told that an increase in AMH after an intervention proves that egg quality or live-birth probability improved.
Stem Cells and Experimental Regenerative Treatments
Stem-cell research has important scientific potential, but clinical claims often move faster than evidence.
Experimental procedures may be marketed for ovarian failure, thin endometrium, testicular failure, or embryo development. The terms “regeneration” and “new eggs” can create unrealistic expectations in patients with few remaining options.
Before considering any stem-cell intervention, patients should ask:
- Is this an approved clinical treatment or a research study?
- Has it demonstrated live births in reliable human research?
- What cells are being used and how are they processed?
- What short- and long-term risks are known?
- Is there ethical and regulatory approval?
- Who is responsible for follow-up?
Experimental treatment should not be sold as established care merely because the patient has a difficult prognosis.
Growth Hormone, DHEA, and Androgen Supplementation
Patients with low ovarian reserve or poor response may be offered growth hormone, DHEA, testosterone, or other pre-treatment supplements.
The biological theories relate to follicle development or ovarian response, but research has not established routine benefit for all poor responders. Preparations, doses, treatment duration, and study populations differ.
These agents can have side effects and may interact with other conditions or medication.
A supplement available without prescription is not automatically harmless or effective. If used, the patient should understand the evidence, intended target, duration, and uncertainty.
Standard ovarian-reserve counselling should not be replaced by the suggestion that supplementation can create follicles that are not biologically available.
Sperm-Selection Add-Ons
Several laboratory methods aim to select sperm beyond standard preparation and ICSI assessment.
These may include:
- High-magnification sperm selection such as IMSI
- Hyaluronic-acid binding selection such as PICSI
- Microfluidic sperm selection
- Magnetic-activated cell sorting
- Selection based on sperm DNA fragmentation or other markers
Some techniques may improve a laboratory parameter or have a possible role in selected male-factor cases. Evidence for routine improvement in live birth is not uniform.
The first step should remain proper male evaluation. A sperm-selection device should not replace investigation of azoospermia, hormonal disorders, varicocele, genetic risk, medication, or surgically retrievable sperm.
The team should explain why a particular method is being recommended and whether the evidence applies to the patient’s diagnosis.
Sperm DNA Fragmentation Testing
Sperm DNA fragmentation tests measure aspects of DNA damage not shown by standard semen analysis.
Testing may be discussed in selected cases, but it should not be offered automatically to every patient with infertility or every couple after one failed IVF cycle.
Different tests use different methods and thresholds. A high result does not identify one universal cause or treatment. A normal result does not guarantee fertilisation, embryo development, or pregnancy.
The test is most useful when the team has a defined clinical question and a realistic plan for how the result may change management.
Embryo Transfer Media and “Embryo Glue”
Some transfer media contain increased concentrations of hyaluronan and are marketed using terms such as “embryo glue.”
The name can suggest that the embryo is physically attached to the uterus, which is not an accurate description of implantation.
Research may show benefit in certain outcomes or patient groups, but effect size, multiple-pregnancy considerations, and cumulative outcomes should be interpreted carefully.
Patients should understand what the product is, whether it is already part of the laboratory’s routine protocol, what evidence supports an extra charge, and whether safer embryo-transfer strategy remains the priority.
Microbiome Testing
Commercial tests may analyse bacteria in the endometrium, vagina, or semen and link particular patterns to implantation or miscarriage.
Microbiome science is developing, but there is no universal definition of an ideal reproductive microbiome, and sampling, laboratory methods, contamination, and interpretation vary.
Detecting bacterial DNA does not automatically prove infection or establish that antibiotic or probiotic treatment will improve live birth.
Testing should not lead to repeated antibiotics without a clear diagnosis. Unnecessary treatment may cause side effects and alter microbial communities without proven reproductive benefit.
When an Add-On May Still Be Reasonable
Uncertain evidence does not mean that every add-on must be prohibited in every situation.
An intervention may be considered when:
- There is a specific medical or laboratory indication
- Evidence supports benefit for a defined subgroup
- Standard options have been reviewed
- Risks and uncertainty are acceptable
- The patient gives informed consent
- Cost is transparent
- Outcome will be documented
- Use complies with regulation and professional guidance
The decision should be made because the patient’s case provides a rationale—not because the add-on is included in a premium package.
Research Must Be Identified as Research
New treatments require clinical research.
Patients may reasonably choose to participate in an ethically approved study, particularly when standard options are limited. However, research should be presented honestly.
Patients should know:
- The intervention is experimental
- The study question
- What is known and unknown
- Whether randomisation is involved
- What costs are covered
- How safety is monitored
- How data will be used
- Whether participation can be withdrawn
The desperation created by infertility should never be used to weaken research consent.
An experimental procedure does not become established simply because a clinic charges for it.
Cost and Opportunity Cost
The financial effect of add-ons extends beyond the additional fee.
Money spent on several unproven interventions in one cycle might otherwise fund medication, cryostorage, a frozen transfer, further diagnostic evaluation, or another standard treatment cycle.
Add-ons can also create opportunity cost through delayed treatment, travel, biopsy, surgery, or weeks of preparation.
For patients with declining ovarian reserve or advanced age, time itself may have clinical value.
The patient should be able to compare:
- Standard treatment alone
- Standard treatment plus the add-on
- Another treatment strategy
- Further evaluation
- Waiting or taking no immediate action
Financial consent is part of informed medical consent.
How Jinemed Introduces Innovation Responsibly
Responsible adoption of new technology requires more than enthusiasm.
The process should include:
- Review of scientific literature and professional guidance
- Definition of the intended patient group
- Assessment of safety and ethical issues
- Laboratory or clinical validation
- Staff training and competency
- Written protocols
- Clear patient information and consent
- Monitoring of outcomes and adverse events
- Periodic re-evaluation as evidence changes
An intervention may move from research to selected clinical use and later to routine practice—or may be abandoned if better evidence shows no benefit.
Changing practice in response to new evidence is not inconsistency. It is the responsibility of evidence-based medicine.
Innovation Without Exploitation
Patients come to fertility centres with hope, urgency, and often a history of loss. These emotions deserve protection.
At Jinemed, innovation should never depend on making a patient feel that declining an add-on means they did not do everything possible.
The team’s responsibility is to explain:
- What is established
- What is promising but uncertain
- What appears ineffective
- What may create safety concerns
- What is experimental
The final decision should reflect the patient’s values and medical situation, but informed choice requires accurate language.
“Advanced,” “personalised,” “natural,” “immune,” “rejuvenation,” and “AI-powered” are descriptions—not evidence of improved live birth.
Evidence Before Add-Ons
Reproductive medicine advances because clinicians and scientists question existing practice and test new ideas. Without innovation, IVF itself would never have developed.
Yet the history of medicine also shows that plausible treatments can fail when studied properly, and some can cause harm.
Jinemed’s philosophy is therefore neither to reject every new technology nor to sell novelty as proof of excellence.
The standard is simple:
- Define the problem.
- Examine the evidence.
- Protect safety.
- Explain uncertainty.
- Respect patient choice.
- Measure meaningful outcomes.
- Change practice when the evidence changes.
Innovation earns its place in patient care through evidence—not through the intensity of its marketing.